Stock Price Quote

MEDICO REMEDIES LTD.

NSE : MEDICOBSE : 540937ISIN CODE : INE630Y01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE51.58-0.76 (-1.45 %)
PREV CLOSE ( ) 52.34
OPEN PRICE ( ) 52.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 547
TODAY'S LOW / HIGH ( )51.23 52.66
52 WK LOW / HIGH ( )35 79.78
NSE51.55-0.9 (-1.72 %)
PREV CLOSE( ) 52.45
OPEN PRICE ( ) 52.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 51.55 (2000)
VOLUME 82290
TODAY'S LOW / HIGH( ) 51.00 53.24
52 WK LOW / HIGH ( )37.18 79.83
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-03 1994
Management Info
Haresh Mehta - Chairman Harshit Mehta - Managing Director
Registered Office

Address 1105/1106, 11th Floor,Hubtown Solaris, Opp Telli Galli,N S Phadke Marg, Andheri (East) ,
Mumbai,
Maharashtra-400069

Phone 022 26821054 / 1055 / 26837116

Email medicoremedies@yahoo.com / info@medicoremedies.com

Website www.medicoremediesindia.com / www.medicoremediesindia.net / www.tabletandcapsules.com

Registrars Details
Cameo Corporate Services Ltd
304 Sai Sadan 3rd Floor,76 - 78 Mody Street,Fort,Mumbai
Listing : BSE, NSE

NEWS

07Oct Medico Remedies secures supply order w
Medico Remedies has secured government supply order worth around $1.78 m..
26Sep Medico Remedies informs about closure
Medico Remedies has informed that pursuant to the SEBI (Prohibition of I..
05Aug Medico Remedies informs about book clo
Medico Remedies has informed that the Register of Members and Share Tran..
23Jun Medico Remedies informs about disclosu
Medico Remedies has informed that the exchange has received the disclosu..
16May Medico Remedies commences work for new
Medico Remedies has commenced work for new factory for manufacturing of..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit25.68100.94
Gross Profit 34.74 135.05
Operating Profit 44.43176.93
Net Sales 526.351509.41

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Procter&Gamble Healt (BSE)
peergroup  5694.85 (1.04%)
M.Cap ( in Cr)9418.57
Haleos Labs (BSE)
peergroup  1385.00 (3.40%)
M.Cap ( in Cr)418.73
Pfizer (BSE)
peergroup  5027.50 (0.90%)
M.Cap ( in Cr)23031.01
Venus Remedies (BSE)
peergroup  786.50 (5.00%)
M.Cap ( in Cr)1051.31
Ajanta Pharma (BSE)
peergroup  2655.30 (1.37%)
M.Cap ( in Cr)33097.95

Shareholding Pattern

PROMOTERS 61.38%
NON-INSTITUTION 38.3%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Medico Remedies Ltd.

Medico Remedies Ltd. was incorporated in the year 1994. Its today's share price is 51.58. Its current market capitalisation stands at Rs 431.35 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1509.41 Cr and Total Income of Rs.1542.12 Cr. The company's management includes Maheshkumar Darji, Hasan Bohra, Anuj Mody, Kunal Tushar Vora, Deepesh Shah, Bharat Rathod, Deepak Vekaria, Rita Mehta, Rishit Mehta, Harshit Mehta, Haresh Mehta.

It is listed on the BSE with a BSE Code of 540937 , NSE with an NSE Symbol of MEDICO and ISIN of INE630Y01024. It's Registered office is at 1105/1106, 11th Floor,Hubtown Solaris, Opp Telli Galli,N S Phadke Marg, Andheri (East) Mumbai-400069, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Pratap R Rajwade, VJ Shah & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.